{
    "nct_id": "NCT05669482",
    "official_title": "A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas",
    "inclusion_criteria": "* Male or female subjects ≥ 18 years of age\n* Histologic or cytologic evidence of metastatic pancreatic ductal adenocarcinoma.\n* An Eastern Cooperative Group (ECOG) performance status ≤ 1\n* Measurable disease according to RECIST 1.1\n* Adequate organ function\n* Adequate cardiac function\n* Agreement to use highly effective method of contraceptive\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with pancreatic neuroendocrine tumors\n* Prior or concomitant treatment for metastatic pancreatic ductal adenocarcinoma\n* Prior treatment with inhibitors of the RAS /MAPK pathway [e.g. MEK inhibitors] or inhibitors of FAK\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks (excluding placement of vascular access)\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Concurrent ocular disorders\n* Active skin disorder that has required systemic therapy within the past 1 year\n* Patients with interstitial lung disease or pulmonary fibrosis or severe lung disease, pulmonary edema, and adult respiratory distress syndrome\n* Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy",
    "miscellaneous_criteria": ""
}